AccessAlpha Worldwide LLC

AccessAlpha serves as an advisor and placement agent for institutional asset managers and investors. We selectively partner with boutique investment firms that offer specialized strategies which deliver alpha to institutional investors. We understand the needs of some of the nation’s most respected investors, and we partner with asset managers that can deliver on those needs. For our manager partners, we offer advisory and distribution services thereby allowing our investment teams to focus exclusively on managing investment portfolios and delivering alpha. Our experienced team has extensive relationships with foundations, endowments, family offices, retirement plans, government agencies and consultants. We are a trusted source with these institutions and our reputation benefits our managers during the fundraising process. The best use of an asset manager’s time is to focus on the investment portfolio. Making investment decisions which benefit client portfolios. Delivering performance within risk expectations. While critical in any investment organization, ancillary responsibilities away from one’s portfolio have the possibility of being alpha detracting and costly. AccessAlpha’s services make asset managers more efficient, benefitting our managers and, ultimately, the managers’ institutional clients. Every member of our team has more than twenty years of experience working with institutional allocators of capital. Most importantly, we have developed relationships and earned the trust, and we are viewed as a unique resource to the sophisticated institutional investment community. Whether its private equity, real estate, hedge funds, venture capital or long-only equity, investors have more choices today than ever. And everyone’s time is valuable. Our team works with our managers in preparing and executing a comprehensive and effective business development and capital raising program. Rare genetic diseases are a significant burden on society through both uncurbable, often fatal genetic diseases in adults and children as well as a large cost on society through disability and childhood mortality. Existing therapeutic platforms do not address the issue adequately and are often symptomatic. Advanced biotherapeutics are key to addressing the challenges of modern-day healthcare – spiraling cost of long-term chronic illness and lack of cures. 4Bio is a London-based firm focused on private equity and venture capital in Life Sciences. 4Bio invests into advanced therapies addressing high unmet medical and social needs. 4Bio’s investment focus pertains to the largest segments across the new generation of therapeutic platforms including gene therapy, cell therapy, RNA-based therapy, targeted therapy, and microbiome.